Erelzi 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/10795
Periodic Safety Update EU Single assessment - 
12/10/2023 
11/12/2023 
Refer to Scientific conclusions and grounds recommending 
/202302 
etanercept 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10795/202302. 
IB/0050 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/12/2023 
generic/hybrid/biosimilar products following 
SmPC, Annex 
II, Labelling 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
assessment of the same change for the reference 
and PL 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0048 
B.II.b.3.z - Change in the manufacturing process of 
07/08/2023 
n/a 
the finished or intermediate product - Other variation 
IAIN/0049/G 
This was an application for a group of variations. 
01/08/2023 
11/12/2023 
Annex II and 
PL 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
Page 2/14 
 
 
 
 
 
 
 
 
 
 
 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0046/G 
This was an application for a group of variations. 
04/05/2023 
n/a 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.b.1.z - Replacement or addition of a 
manufacturing site for the FP - Other variation 
B.II.e.3.b - Change in test procedure for the 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
IB/0045 
B.II.c.z - Change in control of excipients in the 
17/02/2023 
n/a 
Finished Product - Other variation 
Page 3/14 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0043 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/09/2022 
17/07/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II/0042/G 
This was an application for a group of variations. 
21/07/2022 
17/07/2023 
SmPC and PL 
The SmPC section 6.5 has been updated to include the new 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.II.e.1.b.2 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Sterile medicinal products and 
biological/immunological medicinal products 
WS/2271/G 
This was an application for a group of variations 
21/07/2022 
n/a 
syringe, autoinjector and describe the needle shield. 
Editorial changes are also made to section 3, 
pharmaceutical form, of the SmPC to bring it in line with 
the current QRD template version. 
The Package Leaflet (PL) is updated accordingly. 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
Page 4/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
material/intermediate 
II/0040/G 
This was an application for a group of variations. 
21/07/2022 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.4.e - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of an in-process test which may have a significant 
effect on the overall quality of the AS 
IA/0039 
B.II.d.2.b - Change in test procedure for the finished 
20/04/2022 
n/a 
product - Deletion of a test procedure if an 
alternative method is already authorised 
R/0037 
Renewal of the marketing authorisation. 
27/01/2022 
04/04/2022 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of Erelzi 
and PL 
in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
II/0038/G 
This was an application for a group of variations. 
13/01/2022 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
Page 5/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0036 
C.I.11.z - Introduction of, or change(s) to, the 
24/06/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0035/G 
This was an application for a group of variations. 
12/05/2021 
19/10/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0034 
B.II.b.4.f - Change in the batch size (including batch 
18/02/2021 
n/a 
size ranges) of the finished product - The scale for a 
biological/immunological medicinal product is 
increased/decreased without process change (e.g. 
duplication of line) 
IAIN/0033/G 
This was an application for a group of variations. 
30/10/2020 
19/10/2021 
SmPC and PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
Page 6/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
IB/0032 
C.I.2.a - Change in the SPC, Labelling or PL of a 
09/10/2020 
19/10/2021 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
PSUSA/10795
Periodic Safety Update EU Single assessment - 
03/09/2020 
n/a 
PRAC Recommendation - maintenance 
/202002 
etanercept 
IAIN/0031 
B.II.b.1.a - Replacement or addition of a 
28/08/2020 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0030 
B.I.e.5.c - Implementation of changes foreseen in an 
03/08/2020 
30/09/2020 
Annex II 
approved change management protocol - For a 
biological/immunological medicinal product 
IB/0029/G 
This was an application for a group of variations. 
15/07/2020 
30/09/2020 
SmPC 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
Page 7/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0028 
B.II.d.2.a - Change in test procedure for the finished 
12/06/2020 
n/a 
product - Minor changes to an approved test 
procedure 
IAIN/0026 
C.I.11.a - Introduction of, or change(s) to, the 
10/04/2020 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
IA/0025 
B.II.e.6.b - Change in any part of the (primary) 
18/03/2020 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
II/0024/G 
This was an application for a group of variations. 
12/03/2020 
n/a 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test 
method at the site is a biol/immunol method 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
B.II.b.2.z - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Other variation 
Page 8/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0022 
B.IV.1.z - Change of a measuring or administration 
28/01/2020 
n/a 
device - Other variation 
IB/0023 
B.I.a.2.a - Changes in the manufacturing process of 
12/12/2019 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
PSUSA/10452
Periodic Safety Update EU Single assessment - 
19/09/2019 
14/11/2019 
SmPC and PL 
Please refer to Benepali Erelzi 
/201901 
etanercept (biosimilars) 
EMEA/H/C/PSUSA/00010452/201901 EPAR: 
Scientific conclusions and grounds recommending the 
variation to the terms of the marketing authorisation 
IB/0021 
C.I.2.a - Change in the SPC, Labelling or PL of a 
08/10/2019 
30/09/2020 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
II/0018 
B.I.e.2 - Introduction of a post approval change 
26/09/2019 
n/a 
management protocol related to the AS 
IA/0020 
A.5.b - Administrative change - Change in the name 
14/06/2019 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IB/0019 
C.I.2.a - Change in the SPC, Labelling or PL of a 
16/05/2019 
14/11/2019 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Labelling and 
PL 
Page 9/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
IA/0017 
B.II.b.5.z - Change to in-process tests or limits 
10/05/2019 
n/a 
applied during the manufacture of the finished 
product - Other variation 
IB/0015 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
12/04/2019 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IA/0014/G 
This was an application for a group of variations. 
28/03/2019 
n/a 
B.I.a.4.a - Change to in-process tests or limits 
applied during the manufacture of the AS - 
Tightening of in-process limits 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.III.2.c - Change to comply with Ph. Eur. or with a 
national pharmacopoeia of a Member State - Change 
in specifications from a national pharmacopoeia of a 
Member State to the Ph. Eur. 
IB/0013 
C.I.11.z - Introduction of, or change(s) to, the 
19/02/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
Page 10/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10452
Periodic Safety Update EU Single assessment - 
14/02/2019 
n/a 
PRAC Recommendation - maintenance 
/201807 
etanercept (biosimilars) 
IA/0012 
B.II.b.5.a - Change to in-process tests or limits 
04/01/2019 
n/a 
applied during the manufacture of the finished 
product - Tightening of in-process limits 
PSUSA/10452
Periodic Safety Update EU Single assessment - 
06/09/2018 
n/a 
PRAC Recommendation - maintenance 
/201801 
etanercept (biosimilars) 
IA/0010 
B.II.b.3.a - Change in the manufacturing process of 
04/09/2018 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0009/G 
This was an application for a group of variations. 
30/07/2018 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
IB/0008/G 
This was an application for a group of variations. 
30/05/2018 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.4.c - Change to in-process tests or limits 
Page 11/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
28/03/2018 
11/07/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II/0005/G 
This was an application for a group of variations. 
01/02/2018 
n/a 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
Page 12/14 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
IB/0004 
C.I.2.a - Change in the SPC, Labelling or PL of a 
17/11/2017 
11/07/2018 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0003 
B.II.z - Quality change - Finished product - Other 
10/10/2017 
n/a 
variation 
IB/0002/G 
This was an application for a group of variations. 
10/10/2017 
n/a 
B.I.a.2.z - Changes in the manufacturing process of 
the AS - Other variation 
B.I.a.4.c - Change to in-process tests or limits 
applied during the manufacture of the AS - Deletion 
of a non-significant in-process test 
IB/0001/G 
This was an application for a group of variations. 
28/07/2017 
11/07/2018 
SmPC, 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
Labelling and 
PL 
Page 13/14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
Page 14/14 
 
 
 
 
 
 
 
